[{"address1": "Yalelaan 62", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 85 016 3100", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 55, "title": "CEO, President & Executive Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 62, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 49, "title": "Chief Scientific Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 47, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 62, "title": "Chief Development Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 2.95, "open": 2.97, "dayLow": 2.69, "dayHigh": 2.97, "regularMarketPreviousClose": 2.95, "regularMarketOpen": 2.97, "regularMarketDayLow": 2.69, "regularMarketDayHigh": 2.97, "beta": 0.632, "forwardPE": -1.2374429, "volume": 312170, "regularMarketVolume": 312170, "averageVolume": 1858008, "averageVolume10days": 326970, "averageDailyVolume10Day": 326970, "bid": 2.65, "ask": 2.78, "bidSize": 400, "askSize": 300, "marketCap": 71243464, "fiftyTwoWeekLow": 1.131, "fiftyTwoWeekHigh": 6.47, "priceToSalesTrailing12Months": 10.524961, "fiftyDayAverage": 2.492, "twoHundredDayAverage": 1.852705, "currency": "USD", "enterpriseValue": 15412454, "floatShares": 12293023, "sharesOutstanding": 26289100, "sharesShort": 322138, "sharesShortPriorMonth": 10146, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0123000005, "heldPercentInsiders": 0.28581, "heldPercentInstitutions": 0.33103, "shortRatio": 0.11, "shortPercentOfFloat": 0.02, "impliedSharesOutstanding": 26289100, "bookValue": 1.912, "priceToBook": 1.4173641, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -41974000, "trailingEps": -1.57, "forwardEps": -2.19, "enterpriseToRevenue": 2.277, "enterpriseToEbitda": -0.361, "52WeekChange": 0.7483871, "SandP52WeekChange": 0.27320957, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LVTX", "underlyingSymbol": "LVTX", "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "firstTradeDateEpochUtc": 1616765400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f272303e-4305-36b0-b7df-26c82acd7c44", "messageBoardId": "finmb_546792242", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.71, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "totalCash": 95571000, "totalCashPerShare": 3.57, "ebitda": -42675668, "totalDebt": 6313000, "quickRatio": 6.51, "currentRatio": 6.619, "totalRevenue": 6769000, "debtToEquity": 12.335, "revenuePerShare": 0.253, "returnOnAssets": -0.22056, "returnOnEquity": -0.61179, "revenueGrowth": -0.866, "grossMargins": 0.48560002, "operatingMargins": -15.4164295, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-10"}]